TuisMLLCF • OTCMKTS
add
Molecular Partners AG
Vorige sluiting
$6,52
Jaarwisseling
$3,40 - $10,14
Markkapitalisasie
245,02 m USD
Gemiddelde volume
53,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
SWX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(CHF) | Mrt. 2024info | J/J-verandering |
---|---|---|
Inkomste | 2,74 m | -10,23% |
Bedryfskoste | 4,49 m | -17,47% |
Netto inkomste | -11,32 m | 23,37% |
Netto winsgrens | -413,62 | 14,63% |
Wins per aandeel | — | — |
EBITDA | -15,25 m | -5,35% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(CHF) | Mrt. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 174,13 m | -25,06% |
Totale bates | 185,60 m | -24,10% |
Totale aanspreeklikheid | 17,06 m | -23,74% |
Totale ekwiteit | 168,54 m | — |
Uitstaande aandele | 32,87 m | — |
Prys om te bespreek | 1,27 | — |
Opbrengs op bates | -20,65% | — |
Opbrengs op kapitaal | -22,53% | — |
Kontantvloei
Netto kontantverandering
(CHF) | Mrt. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -11,32 m | 23,37% |
Kontant van bedrywe | -17,05 m | -3,05% |
Kontant van beleggings | 17,61 m | 422,58% |
Kontant van finansiering | -300,00 k | -1,01% |
Netto kontantverandering | 1,04 m | 107,39% |
Beskikbare kontantvloei | -11,21 m | -30,15% |
Meer oor
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Gestig
2004
Webwerf
Werknemers
168